Most major KIT mutations occur in exon 11, and this mutation is favorable for imatinib therapy; however, patients with a KIT mutation in exon 9, which accounts for 10–20% of GIST cases, were poor responders to imatinib therapy [21,22]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.